Therapeutic Plasma Exchange for Chronic Fatigue (ME/CFS)
Outpatient TPE for the immune-driven and post-viral phenotype of myalgic encephalomyelitis / chronic fatigue syndrome.
Important: Therapeutic plasma exchange is not covered by insurance in our outpatient setting. TPE at Purety Clinic is fee-for-service. We provide transparent pricing at consultation and a superbill you may submit for potential out-of-network reimbursement.
Why TPE for ME/CFS
Myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) has long suffered from the absence of a single mechanistic explanation — but the working model has converged in recent years around a combination of post-viral autoimmunity, persistent neuroinflammation, mitochondrial dysfunction, and (in many cases) dysautonomia. The Norwegian rituximab and cyclophosphamide trials made the autoimmune hypothesis impossible to ignore: a meaningful subset of ME/CFS patients responded to B-cell depletion in a way that points squarely at antibody-mediated disease.
The post-COVID era has only sharpened this picture. Long COVID and ME/CFS share enough clinical and immunological features that many researchers consider Long COVID a viral-trigger model for understanding ME/CFS itself. The same autoantibodies (against GPCRs and other targets), the same patterns of post-exertional malaise, the same fatigue-cognition-dysautonomia triad show up in both populations.
TPE addresses the immune and inflammatory components directly — removing autoantibodies, immune complexes, and inflammatory cytokines from circulation. For ME/CFS patients with a clear post-viral onset, autoantibody positivity, or strong dysautonomic features, TPE is one of the few interventions that targets the upstream drivers rather than the downstream symptoms.
What the Research Shows
Direct trials of TPE specifically for ME/CFS are still limited, but the supporting evidence base is substantial. The Norwegian rituximab program (Fluge and Mella) demonstrated that B-cell depletion produced clinical response in a subset of ME/CFS patients — the strongest argument yet for an autoantibody driver. Plasma-based approaches (TPE and immunoadsorption) have shown similar promise in case series and in the Charité Berlin Long COVID program (which substantially overlaps with the ME/CFS population).
Investigators including Dr. Wolfgang Marx and Dr. Bhupesh Prusty have published work suggesting that herpesvirus reactivation (HHV-6, EBV) drives a sustained inflammatory and autoimmune response in ME/CFS — a context in which removing the resulting inflammatory plasma fraction has clear mechanistic logic.
ME/CFS is not currently an FDA-approved indication for TPE. We offer it as an off-label, evidence-informed adjunctive tool with full informed consent. Response is variable. We are honest with every patient about that uncertainty.
Who Is a Candidate for TPE for ME/CFS?
- Established ME/CFS diagnosis (typically by IOM/SEID, Canadian, or Fukuda criteria)
- Identifiable post-viral or post-infectious onset, OR positive autoantibody panel, OR strong dysautonomic features
- Failed or unable to tolerate standard ME/CFS supportive care
- Adequate functional reserve to tolerate the visit and post-procedure recovery (we screen for severity and pacing needs)
- Realistic expectations and willingness to undergo lab monitoring through the protocol
Final candidacy is determined at consultation by Dr. Birch after review of your full clinical history, lab work, and treatment goals. TPE is not appropriate for every patient and we will tell you so directly when it is not the right tool.
What the ME/CFS Protocol Looks Like
A typical ME/CFS TPE protocol begins with 5 outpatient sessions delivered weekly or every other week, with substantial attention to pacing — we space sessions further apart for severe ME/CFS patients to avoid post-exertional malaise. Concurrent IV nutritional support is common.
Reassessment happens after the initial course with both standardized symptom scoring and lab markers where applicable (autoantibody panels, inflammatory markers, viral reactivation panels). Responders typically continue with a maintenance schedule tailored to their pattern; non-responders are redirected to other tools — IVIG, low-dose naltrexone, antiviral strategies, mast cell stabilization — depending on the underlying picture.
Curious about the TPE procedure itself?
See our complete therapeutic plasma exchange overview, including how each session works, what the equipment looks like, and what to expect on the day of your visit.
Read the Full TPE OverviewFrequently Asked Questions: TPE for ME/CFS
From the Blog
All Articles
Two Licensed Naturopathic Medical Doctors. One Practice.
The naturopathic medical doctors caring for our patients at Purety Family Medical Clinic.
Dr. Jonathan Birch, NMD, RMSK
Founder · Naturopathic Medical Doctor
Licensed Naturopathic Medical Doctor and Registered in Musculoskeletal Sonography. Practicing root-cause integrative medicine since 2014. Areas of focus include FMT and microbiome restoration, hormone and thyroid optimization, autoimmune and Long COVID protocols, ozone and IV nutrient therapy, and PRP and regenerative injections.
Read Dr. Birch's full bioDr. Dena Birch, NMD
Naturopathic Medical Doctor · Women's Health & Pediatrics
Licensed Naturopathic Medical Doctor leading our women's health and holistic pediatric care. Areas of focus include perimenopause and bioidentical hormone therapy, PCOS and thyroid, fertility support, pediatric eczema, immune issues and recurrent infections, and gentle well-child care for families.
Read Dr. Dena's full bioDiscuss TPE for ME/CFS with Dr. Birch
Call (805) 500-8300 or submit a consultation request. Remote consultations available for patients outside Santa Barbara.
(805) 500-8300